You are here

New Edition of Handbook on Injectable Drugs Now Available

October 7, 2010 -- In the ever-changing, data-intense, split-second decision world of parenteral drugs, pharmacists rely on the Handbook on Injectable Drugs as a premier resource. The 16th edition of this vital touchstone is now available, published by the American Society of Health-System Pharmacists (ASHP).

The Handbook is the leading injectable drug guide, trusted, turned to and touted the world over for its intuitive, easy to use layout, and its accessible organization and presentation of data.

The 16th edition brings together a wealth of information on 349 parenteral drugs commercially available in the United States and in other countries. Compatibility, stability, storage and preparation data for each have been painstakingly referenced and clearly presented. There are 64 new references, for a total of 2,788.

The book is edited by Lawrence A. Trissel, FASHP, as has been the case for over 30 years of continuous publication. Mr. Trissel and the Handbook on Injectable Drugs continue to set the standard for comprehensiveness, speed, and trustworthiness.

The Handbook is also available in a CD-ROM format, which can be bought as a package with the print version. The CD allows users to screen up to five drugs/solutions for compatibility simultaneously, access original research through PubMed, and search concise table summaries of compatibility results.

To place orders for the book, ISBN 978-1-58528-248-7and view additional material, please visit Or, please email or call 1-866-279-0681 (US & Canada), 001-301-664-8700 (International).

Source: American Society of Health System Pharmacists

Recent Headlines

Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial